Two out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 28 points (0.2%) at 17,783 as of Friday, Oct. 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,543 issues advancing vs. 1,349 declining with 225 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is unchanged. A company within the industry that increased today was

GlaxoSmithKline

(

GSK

), up 1.3%. On the negative front, top decliners within the industry include

Valeant Pharmaceuticals International

(

VRX

), down 10.8%,

Pfizer

(

PFE

), down 2.0% and

Bristol-Myers Squibb Company

(

BMY

), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AbbVie

(

ABBV

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $5.87 (10.8%) to $59.97 on heavy volume. Thus far, 14.1 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.2 million shares. The stock has ranged in price between $57.66-$59.99 after having opened the day at $57.94 as compared to the previous trading day's close of $54.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $87.0 billion and is part of the health care sector. Shares are down 17.3% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TST Recommends

2. As of noon trading,

Johnson & Johnson

(

JNJ

) is up $0.50 (0.5%) to $101.87 on average volume. Thus far, 3.7 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $101.05-$102.12 after having opened the day at $101.50 as compared to the previous trading day's close of $101.37.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $277.4 billion and is part of the health care sector. Shares are down 3.1% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. Among the primary strengths of the company is its expanding profit margins over time. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Allergan

(

AGN

) is up $7.12 (2.3%) to $311.50 on heavy volume. Thus far, 5.2 million shares of Allergan exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $305.63-$317.04 after having opened the day at $310.00 as compared to the previous trading day's close of $304.38.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $112.5 billion and is part of the health care sector. Shares are up 18.2% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates

Allergan

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Allergan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).